Edison says sees Celyad year-end cash of 107 million euros

28 January 2016

Investment research firm Edison said it expects the Belgian biotech company Celyad to have 2015 year-end cash of about 107 million euros ($116.8 million).

Following the company’s hinting that the C-Cure cardiac regeneration project might be fully partnered from 2017, the broker said it has a new indicative value of $95 per share as it awaits Phase III CHART-1 C-Cure data, due mid-2016, before the Phase I CAR T-cell study completes.

Edison lowered its value estimate for the product to 846 million euros ($923.4 million) from the earlier estimate of 953 million euros given that the company will likely pick a partner for marketing the product in the USA. The indicative valuation now assumes that C-Cure is partnered after Phase III in Europe with some upfront fees; C-Cure was always assumed to be partnered for US marketing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK